Previously in Part I
We established the regulatory framework (Category 1 ≠ FDA approved), the Phase 1/2/3 evidence standard, and reviewed the 7 peptides with at least some human trial data — including the one FDA-approved compound (PT-141) and the one that completed Phase 3 and failed (AOD-9604). Read Part 1 here →
Clinical Takeaway — Part II
The Compounds Where the Evidence Gets Thin — Fast
Tiers IV and V contain 10 of the 17 peptides. Of those, 5 have zero published human trials of any phase—they are being prescribed based entirely on animal data.
BPC-157, the most hyped compound on the list, has approximately 30 human subjects across all published research — no randomized trials, a canceled Phase 1 with no published results.
Melanotan II is the compound where the FDA's concern is most defensible: melanoma case reports, cardiovascular events, and no Phase 3 data.
RFK Jr.'s procedural argument may have legal merit. Winning it does not make any of these compounds safe or effective. The evidence base is unchanged by the reclassification.
Tiers IV & V: Where the Evidence Gets Thin
If Tiers I–III showed a spectrum from “approved and proven” down to “early-phase human data only,” Tiers IV and V represent something categorically different: compounds being prescribed at scale where the human evidence is either minimal, non-replicable, or entirely absent. This is where the hype-to-evidence gap becomes clinically significant.
IV Minimal Human Data 1–3 small uncontrolled studies, or non-replicable foreign literature only |
|---|
BPC-157 Body Protection Compound-157 · gastric peptide fragment ~30 Total Human Subjects The widest hype-to-evidence gap on this list. A 2025 systematic review in HSS Journal® (The Musculoskeletal Journal of Hospital for Special Surgery) found 36 relevant studies — 35 preclinical, 1 clinical. Total human subjects across all published BPC-157 research: approximately 30, across three uncontrolled pilot studies. A Phase 1 trial registered in 2015 (NCT02637284, 42 subjects) canceled its submission and never published results — with no public explanation. Zero randomized controlled trials of any kind exist. The angiogenic mechanisms that make it exciting in rodents also carry a theoretical pro-oncogenic implication that has never been evaluated in human safety studies. |
TB-500 (Thymosin Beta-4 Fragment) Actin sequestration, angiogenesis · WADA prohibited Fragment — Not Studied in Humans TB-500 is not Thymosin Beta-4 — it is a synthetic fragment of the parent molecule. RegeneRx ran Phase 2 trials of the full-length Tβ4 for cardiac repair and wound healing. That data does not transfer: the fragment may have different pharmacology and bioavailability than the full protein. For TB-500 specifically, there are no published human trials of any phase. WADA added it to the Prohibited List in 2018 under the growth factors and growth factor modulators category as an unapproved substance. |
Semax & Selank Russian neuropeptides — BDNF upregulation & anxiolytic signaling Russian Literature Only Both were developed at the same Russian institute, registered in Russia and Ukraine for cognitive disorders and anxiety, and studied in a literature that does not meet Western GCP standards — unclear randomization, limited blinding, single-institution origins, and no independent replication. No Western research group has run a blinded, placebo-controlled trial of either compound. The cognitive enhancement and anxiolytic claims in U.S. wellness marketing have zero controlled trial backing by any recognized regulatory standard. |
GHK-Cu (Injectable) Copper tripeptide · collagen synthesis modulation No Injectable Human Data Category 1 for topical use, Category 2 for injection — and that distinction is actually one of the FDA’s more defensible decisions here. Topical copper peptides have small published dermatology studies with some wound healing and photoaging signal. Injectable GHK-Cu has a fundamentally different systemic exposure profile with no human safety data to evaluate it. The route-specific restriction reflects a real pharmacological gap, not bureaucratic arbitrariness. |
V No Human Data or Active Safety Concern Preclinical only, or adverse event signals without resolution |
|---|
MOTS-C Mitochondria-derived peptide · AMPK activation No Human Trials Identified in 2015, with genuinely novel biology as an exercise mimetic. As of early 2026, no published Phase 1 clinical trials exist — no human pharmacokinetics, no safety data of any kind. It is being prescribed through compounding pharmacies for metabolic health and longevity based entirely on mouse studies. Administering a compound with zero human safety data outside an IND framework is not cutting-edge medicine. It is an experiment on patients without their informed consent to participate in an experiment. |
KPV α-MSH tripeptide · NF-κB inhibition No Human Trials Well-characterized anti-inflammatory mechanism in preclinical IBD and skin inflammation models. Zero published human studies — not a pilot, not a case series, not a PK study. It is being prescribed for Crohn's disease and ulcerative colitis, conditions for which we have actual evidence-based therapies. The history of IBD treatment includes multiple compounds that showed excellent efficacy in murine colitis models and failed to translate, some causing harm in the process. |
Epitalon Synthetic tetrapeptide · telomerase activation No Independent Human Trials Developed in 1980s Russia, with claims spanning telomere lengthening, anti-cancer effects, and general anti-aging. The published literature comes overwhelmingly from a single research group (Khavinson et al.) — a major red flag for independent replication. No blinded, placebo-controlled trial by any independent group exists. The telomerase activation claims rest on cell culture data, and telomerase activation in healthy somatic cells carries a theoretical oncogenic risk never evaluated in human safety studies. |
LL-37 Human cathelicidin · antimicrobial peptide No Systemic Human Data A naturally occurring human antimicrobial peptide with legitimate endogenous biology and small topical wound-healing studies. The problem is that systemic administration is a pharmacologically distinct — and uncharacterized — scenario. LL-37 has known pro-inflammatory effects in certain immune contexts; it is a bidirectional signaling molecule, not simply a beneficial immunostimulant. No human safety data exists for any injected or systemic formulation. |
Melanotan II (MT-II) Non-selective melanocortin agonist · MC1R–MC4R ⚠ Active Safety Concern The compound where the FDA’s concern is most defensible. Non-selective MC receptor activation produces a profile that includes spontaneous erections (MC4R), melanin stimulation (MC1R), and cardiovascular effects. Multiple case reports link MT-II to melanoma, changing nevi, priapism, and CV events. The melanoma connection is mechanistically plausible — MT-II activates the same cellular pathway UV radiation uses to drive melanin production, potentially accelerating transformation in at-risk melanocytes. No Phase 3 trial has been completed. The adverse event signal is more developed here than anywhere else on this list — and it is not reassuring. |
The Full Scorecard
All 17 Category 2 peptides, assessed against the FDA's Phase 1/2/3 evidentiary standard. "Claimed use" reflects wellness market marketing, not any approved indication.
17 Category 2 Peptides — Evidence at a Glance
Assessed against FDA Phase 1/2/3 standard · "Claimed use" = wellness market, not approved indication
Peptide | Claimed Use | Best Available Human Evidence | Grade |
|---|---|---|---|
PT-141 (Bremelanotide) | Sexual dysfunction | Phase 3 RCTs, n≈1,267 | FDA Approved |
AOD-9604 | Fat loss | Phase 2b/3 — negative primary outcome | Phase 3 — Negative |
Thymosin Alpha-1 | Immune optimization | RCTs in HBV/HCV (3,000+ pts) — different indication | Phase 2/3 (Wrong Indication) |
CJC-1295 | Anti-aging, body comp | Phase 1 PK study, n=21 only | Phase 1 Only |
Ipamorelin | GH optimization | Phase 1/2 in post-surgical patients; discontinued for lack of efficacy; adverse events in high-risk surgical population | Phase 1/2 + Signal |
GHRP-2 | Muscle, anti-aging | Phase 1/2; adverse events in high-risk patient populations; approved in Japan as diagnostic agent only | Phase 1/2 + Concern |
GHRP-6 | GH release, muscle | Small Phase 1/2 only | Phase 1/2 Only |
BPC-157 | Tendon, gut repair | ∼30 total human subjects; zero RCTs | ∼30 Human Subjects |
TB-500 (Tβ4 fragment) | Injury healing | Fragment unstudied; parent molecule Phase 2 only | Fragment Not Studied |
Semax | Cognitive enhancement | Russian literature only; no independent RCTs | Non-Generalizable |
Selank | Anxiety, cognition | Russian literature only; no replication | Non-Generalizable |
GHK-Cu (injectable) | Anti-aging, repair | Topical data only; no injectable human studies | No Injectable Data |
MOTS-C | Metabolic, longevity | No published human studies | No Human Data |
KPV | IBD, inflammation | No published human studies | No Human Data |
Epitalon | Anti-aging, telomeres | Single Russian group; no independent RCTs | No Independent Trials |
LL-37 | Immune support | Topical only; no systemic human data | No Systemic Data |
Melanotan II | Tanning, sexual fn | No Phase 3; melanoma & CV events reported | Active Safety Concern |
What Should We Actually Think?
The RFK Jr. critique has a genuine legal leg to stand on. The FDA is only supposed to place compounds on Category 2 when there is a meaningful safety signal. For several of these peptides — particularly BPC-157, KPV, and MOTS-C — the agency's own documentation acknowledged that there was simply no human data to evaluate rather than specific evidence of harm. Multiple lawsuits make this procedural argument with real legal force.
But winning a procedural argument does not establish that the compounds are safe and effective. You can win the former while the latter remains entirely unanswered. And in this debate, those two things are being conflated constantly. The gray market is a real harm — regulated pharmacy access is genuinely safer than buying vials from overseas supplement vendors. But "safer than completely unregulated" is a very low bar, and it is not the same claim as "safe and effective at the doses being prescribed."
The Missed Opportunity
A properly structured expanded access or registry program could generate the human safety and efficacy data these compounds desperately lack — while providing regulated access to patients who want it. Instead, a blanket reclassification sends an implicit signal that these compounds are proven, with no systematic data collection and no mechanism to find out when something goes wrong. The Peptide Wild West doesn't become less wild just because the sheriff waves people through the gate.
Some of these peptides may eventually prove genuinely useful — the preclinical signals on BPC-157, MOTS-C, and KPV are interesting enough to warrant formal human study. The tragedy is that the commercial incentive to run that research barely exists, most of these compounds cannot be patented, and the political path of least resistance is to declare victory and prescribe without ever answering the scientific question. Patients who venture in deserve to know which territory is mapped and which isn't.
Part 2 References
Sources & Further Reading
BPC-157
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J®: The Musculoskeletal Journal of Hospital for Special Surgery. 2025;21:485–495. doi:10.1177/15563316251355551
Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1987–2004. doi:10.2174/1381612824666180504110537
ClinicalTrials.gov. BPC-157 Phase 1 Safety Study. NCT02637284. Status: Canceled. clinicaltrials.gov
TB-500 / Thymosin Beta-4
Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. doi:10.1038/nature05383 Full-length Tβ4 data; does not transfer to the TB-500 fragment.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. doi:10.1016/j.molmed.2005.07.004
World Anti-Doping Agency (WADA). 2018 Prohibited List — Summary of Major Modifications (S2.3: Thymosin-β4 and its derivatives, e.g. TB-500). wada-ama.org
Semax & Selank
Akhapkina VI, Akhapkin RV. [Semax in the treatment of patients with cerebrovascular diseases.] Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(3):14–19. Russian-language publication. Not independently replicated under Western GCP standards.
Semenova TP, Kozlovskaya MM, Zuikov AV, Semenov MV. [Selank — a new anxiolytic peptide drug.] Eksp Klin Farmakol. 2010;73(8):2–6. Russian-language publication. Not independently replicated under Western GCP standards.
GHK-Cu (Injectable)
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108 Topical data only. Injectable route has no published human safety studies.
U.S. Food and Drug Administration. Category 2 Designation for GHK-Cu (Injectable Route). PCAC Review, 2024.
MOTS-C
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
Foundational rodent study. No human clinical trials published as of early 2026.
KPV
Catania A, Lonati C, Sordi A, et al. The peptide alpha-MSH has specific receptors in brain regions involved in the pathophysiology of experimental sepsis. Peptides. 2010;31(4):743–748. doi:10.1016/j.peptides.2010.01.011
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331. doi:10.1002/ibd.20334
No published human clinical trials for KPV for any indication as of early 2026.
Epitalon
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. doi:10.1023/a:1025493705728
Single research group (Khavinson et al.). No independent Western replication.
Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006;5(7):577–584. doi:10.1038/nrd2081
Contextualizes telomerase activation risk in somatic cells.
LL-37
Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22–35. doi:10.1016/j.cellimm.2012.11.009
Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19(5):311–332. doi:10.1038/s41573-019-0058-8
Melanotan II
Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie Drugs' and 'sun-tan jabs'? Br J Dermatol. 2010;163(3):451–455. doi:10.1111/j.1365-2133.2010.09891.x
Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1169–1173. doi:10.3109/15563650.2012.740024
Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784. doi:10.1016/0024-3205(96)00160-9
Verver D, Topsakal V, Hendricksen K, Mooij CM. The tanning drug Melanotan II is associated with melanoma: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2018;32(5):e183–e184. doi:10.1111/jdv.14686
Disclosure: This post is for informational and educational purposes only. It does not constitute medical advice and should not be interpreted as a recommendation for or against any specific therapy. Drug development evidence and regulatory status can change. Always consult a licensed physician before making treatment decisions. The author has no financial relationship with any pharmaceutical, compounding pharmacy, or peptide vendor referenced in this article.